NCT05004259View on ClinicalTrials.gov

The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

September 21, 2024

Study Completion Date

September 21, 2024

Conditions
Hemolytic Anemia
Interventions
DRUG

Daratumumab / Hyaluronidase Injection

Subcutaneous injection of daratumumab and hyaluronidase

Trial Locations (1)

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

Dartmouth-Hitchcock Medical Center

OTHER